Natco Pharma net jumps to ₹320 crore
The Hindu
HYDERABAD
Natco Pharma has posted a consolidated net profit of ₹320 crore for the quarter ended June, a manifold increase from ₹75 crore in the year earlier period.
The net profit came as the total revenue rose 115% to ₹918.9 crore (₹427.3 crore). Export sales of Lenalidomide product, which is indicated in the treatment of certain cancer, to the U.S. was a major contributor to the revenue and profitability during the quarter. Pharma domestic formulations business remained steady, the company said.
A sharp rise in formulation exports to ₹736.9 crore (₹145.4 crore) boosted the revenue even as contribution of API at ₹50.8 crore (₹61.6 crore) and formulations (domestic market) at ₹88.5 crore (₹200.6 crore) declined.
On the expense side, there was a one-time cost associated with retirement schemes and higher than usual research and development costs for product development, it said.
The company has declared an interim dividend of ₹3.50 per equity share (of ₹2 each) for 2022-23. The record date is fixed as August 22 and the interim dividend will be paid from August 30.
Bangladesh asks Adani Power to resume full supplies from Jharkhand plant amid payment disputes and low demand.
Rupee strengthens to 86.84 against the dollar amid trade war fears, market volatility, and RBI intervention.
WazirX announced the completion of its asset rebalancing process and urged investors to support its restructuring scheme.
Vespa introduces luxury scooter portfolio in India, unveiling special editions inspired by Indian artistry and opulence.
Dentzz Dental utilizes AI for precision care, leading to increased efficiency, accuracy, and patient satisfaction in dental treatments.
Former CEA Arvind Subramanian critiques RBI policies, fiscal framework, income tax cuts, and weak private investment in India.
President Trump imposes 25% tariffs on steel and aluminium imports, affecting India and prompting concerns over trade relations.
CEA highlights Southern States' economic prowess, urging benchmarking against global standards and emphasizing need for skill improvement.
The Union Budget unveiled on February 1, 2025, has come at a time of unprecedented global uncertainty and a flagging domestic economy. The real GDP growth is estimated at 6.4% for 2024-25 and between 6.3-6.8% for 2025-26, a far cry from >8 percent growth required annually to make India a developed nation by 2047. While much attention has been devoted to the demand stimulus through income tax cuts, not enough is said about the proposed reforms in urban development, tariff rationalisation, and regulatory simplification aimed at making Indian cities and corporates more competitive. Since the majority of economic activity is located in cities (urban areas account for ~55% of GDP) and produced by large corporates (~40% of the national output and 55% of India’s exports), the above-mentioned reforms have a pivotal role in improving India’s trend growth rate. Below we unpack each reform.
IHCL unveils Taj Bandstand luxury hotel project in Mumbai after 17 years, set to be iconic landmark.
Government and LIC selling majority stake in IDBI Bank, with due diligence process underway for potential investors.
Prime Minister Modi's meetings with President Trump may lead to tariff reductions on U.S. goods like pecan nuts.
President Trump announces 25% tariff on steel and aluminium imports, minimal impact on Indian steel industry.